RIGEL PHARMACEUTICALS INC — Regulatory Filings 2022

Aug 3, 2022

S-8 1 tm2222340d1_s8.htm FORM S-8

As filed with the Securities and Exchange Commission on August 3, 2022

Registration No. 333-

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	94-3248524
(State of Incorporation)	(I.R.S. Employer Identification No.)

1180 Veterans Boulevard

South San Francisco, California 94080

(Address of principal executive offices, including zip code)

Rigel Pharmaceuticals, Inc. Inducement Plan, as Amended

Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as Amended

(Full title of the plan)

Raul R. Rodriguez

President and Chief Executive Officer

Rigel Pharmaceuticals, Inc.

1180 Veterans Boulevard

South San Francisco, California 94080

(650) 624-1100

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Carlton Fleming

Sidley Austin LLP

555 California Street, Suite 2000

San Francisco, California 94104

(415) 772-1207

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨ (Do not check if a smaller
reporting company)	Smaller reporting company	¨
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering: (i) an additional 626,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company” or the “Registrant”) to be issued pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended (the “Inducement Plan”); and (ii) an additional 5,000,000 shares of Common Stock of the Registrant to be issued pursuant to the Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan,, as amended (the “2018 Plan,” and the Inducement Plan and the 2018 Plan, together, the “Plans”)). The shares of the Registrant’s Common Stock previously reserved for issuance under the Plans were registered, as applicable, on the Registrant’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on March 1, 2022 (File No. 333-263187) , June 21, 2021 (File No. 333-257226) , August 4, 2020 (File No. 333-240371) , August 7, 2019 (File No. 333-233064) , August 8, 2018 (File No. 333-226700) , November 7, 2017 (File No. 333-221400) , March 7, 2017 (File No. 333-216516) , and November 1, 2016 (File No. 333-214370) , respectively (the “Prior Form S-8s”).

This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Form S-8s relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Form S-8s, to the extent relating to the registration of Common Stock issuable under the Plans, are incorporated herein by reference and made part of this Registration Statement on Form S-8, except as amended hereby.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

| · | The Registrant’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021, filed with the Commission on March 1,
2022 ; |
| --- | --- |
| · | The Registrant’s Current Reports on Form 8-K filed with the
Commission on January 10, 2022 , January 28, 2022 , February 17, 2022 , May 23, 2022 , June
8, 2022 , June
23, 2022 , July
25, 2022 and August 2, 2022 (with respect to Items 1.01 and 2.03) ;
and |
| · | The description of the Registrant’s Common Stock contained in the
Registrant’s registration statement on Form 8-A
filed with the Commission on October 3, 2000 , including any amendments or reports filed for the purpose of updating
such description. |

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

Field: Page; Sequence: 2

Field: /Page

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits.

Exhibit Number
4.1(1)	Amended
and Restated Certificate of Incorporation of the Company.
4.2(2)	Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of the Company.
4.3(3)	Certificate
of Amendment to the Amended and Restated Certificate of Incorporation of the Company.
4.4(4)	Amended
and Restated Bylaws of the Company.
4.5(5)	Specimen
Common Stock Certificate of the Company.
5.1*	Opinion of Sidley Austin LLP.
23.1*	Consent of Independent
Registered Public Accounting Firm.
23.2*	Consent of Sidley Austin LLP is contained in Exhibit 5.1 to this
Registration Statement.
24.1*	Power of Attorney is contained on the signature pages to this
Registration Statement.
99.1(6)	Rigel
Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended.
99.2(7)	Rigel
Pharmaceuticals, Inc. Inducement Plan, as amended.
107*	Calculation of Filing Fee Table.

| (1) | Document incorporated by reference to the Company’s Current Report on
Form 8-K (No. 000-29889), filed with the Commission on June 24, 2003. |
| --- | --- |
| (2) | Document incorporated by reference to the Company’s Current Report on Form 8-K (No. 000-29889),
filed with the Commission on May 29, 2012. |
| (3) | Document incorporated by reference to the Company’s Current Report on Form 8-K (No. 000-29889),
filed with the Commission on May 18, 2018. |
| (4) | Document incorporated by reference to the Company’s Current Report on Form 8-K (No. 000-29889),
filed with the Commission on February 2, 2007. |

| (5) | Document incorporated by reference to the Company’s Current Report on
Form 8-K (No. 000-29889), filed with the Commission on June 24, 2003. |
| --- | --- |
| (6) | Document incorporated by reference to the Company’s Quarterly Report on Form 10-Q (No. 000-29889),
filed with the Commission on August 3, 2021. |
| (7) | Document incorporated by reference to the Company’s Form 10-K (No. 000-29889),
filed with the Commission on March 6, 2018. |
| * | Filed herewith. |

Field: Page; Sequence: 3

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on August 3, 2022.

RIGEL PHARMACEUTICALS, INC.
By:	/s/ Raul R. Rodriguez
	Raul R. Rodriguez
	Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Raul R. Rodriguez and Dean Schorno, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Raul R.
Rodriguez	President, Chief Executive Officer and	August 3, 2022
Raul R. Rodriguez	Director (Principal Executive Officer)
/s/ Dean Schorno	Chief Financial Officer (Principal Financial and Accounting Officer)	August 3, 2022
Dean Schorno
/s/ Gary A.
Lyons	Chairman of the Board of Directors	August 3, 2022
Gary A. Lyons
/s/ Kamil Ali-Jackson	Director	August 3, 2022
Kamil Ali-Jackson
/s/ Alison L.
Hannah	Director	August 3, 2022
Alison L. Hannah
/s/ Brian L.
Kotzin	Director	August 3, 2022
Brian L. Kotzin
/s/
Gregg A. Lapointe	Director	August 3, 2022
Gregg A. Lapointe
/s/ Walter H.
Moos	Director	August 3, 2022
Walter H. Moos
/s/ Jane Wasman	Director	August 3, 2022
Jane Wasman

Field: Page; Sequence: 4; Options: Last

Field: /Page